Evidence map›Paper›PMID 20360428›Full record

ArticleJournal of applied physiology (Bethesda, Md. : 1985)2010

Skeletal muscle dysfunction in muscle-specific LKB1 knockout mice.

David M Thomson, Chad R Hancock, Bradley G Evanson, Steven G Kenney, Brandon B Malan, Anthony D Mongillo, Jacob D Brown, Squire Hepworth, Natasha Fillmore, Allen C Parcell and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of applied physiology (Bethesda, Md. : 1985), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 44 citations in OpenAlex.

  1. The AMPK Pathway: Molecular Rejuvenation of Metabolism and Mitochondria.Annual review of cell and developmental biology · 2025
    Review
  2. Article
  3. Review
  4. Sarcopenic obesity: emerging mechanisms and therapeutic potential.Metabolism: clinical and experimental · 2023
    Review
  5. Review
  6. Article
  7. AMP-Activated Protein Kinase (AMPK) at the Crossroads Between COInternational journal of molecular sciences · 2020
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. AMPK in skeletal muscle function and metabolism.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018
    Review
  14. Article
  15. Article
  16. Article
  17. Deletion of Lkb1 in Renal Tubular Epithelial Cells Leads to CKD by Altering Metabolism.Journal of the American Society of Nephrology : JASN · 2016
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

David M ThomsonDepartment of Physiology and Developmental Biology, 589 WIDB, Brigham Young University, Provo, UT 84602, USA. david_thomson@byu.edu
Chad R Hancock
Bradley G Evanson
Steven G Kenney
Brandon B Malan
Anthony D Mongillo
Jacob D Brown
Squire Hepworth
Natasha Fillmore
Allen C Parcell
David L Kooyman
William W Winder
Academy of Nutrition and Dietetics · USBrigham Young University · US

Funding

Regulation of Skeletal Muscle LKB1R01AR051928 · NIAMS · BRIGHAM YOUNG UNIVERSITY · PI WINDER, WILLIAM · 2006 to 2010
$1.6M
NIAMS NIH HHS AR-51928
6 · The paper itself

Abstract

Liver kinase B1 (LKB1) is a tumor-suppressing protein that is involved in the regulation of muscle metabolism and growth by phosphorylating and activating AMP-activated protein kinase (AMPK) family members. Here we report the development of a myopathic phenotype in skeletal and cardiac muscle-specific LKB1 knockout (mLKB1-KO) mice. The myopathic phenotype becomes overtly apparent at 30-50 wk of age and is characterized by decreased body weight and a proportional reduction in fast-twitch skeletal muscle weight. The ability to ambulate is compromised with an often complete loss of hindlimb function. Skeletal muscle atrophy is associated with a 50-75% reduction in mammalian target of rapamycin pathway phosphorylation, as well as lower peroxisome proliferator-activated receptor-alpha coactivator-1 content and cAMP response element binding protein phosphorylation (43 and 40% lower in mLKB1-KO mice, respectively). Maximum in situ specific force production is not affected, but fatigue is exaggerated, and relaxation kinetics are slowed in the myopathic mice. The increased fatigue is associated with a 30-78% decrease in mitochondrial protein content, a shift away from type IIA/D toward type IIB muscle fibers, and a tendency (P=0.07) for decreased capillarity in mLKB1-KO muscles. Hearts from myopathic mLKB1-KO mice exhibit grossly dilated atria, suggesting cardiac insufficiency and heart failure, which likely contributes to the phenotype. These findings indicate that LKB1 plays a critical role in the maintenance of both skeletal and cardiac function.

Indexed as

Muscle FatigueAMP-Activated Protein KinasesAnimalsMiceMice, KnockoutMuscle, SkeletalMuscular DiseasesProtein Serine-Threonine KinasesAMP-Activated Protein KinasesProtein Serine-Threonine KinasesStk11 protein, mouse

Identifiers

PMID20360428
PMCPMC2886679
OpenAlexW2162287059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.